PHILADELPHIA - Vincent Lo Re, MD, MSCE, an assistant professor of Medicine in the division of Infectious Diseases and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania, has been awarded a $3 million grant from the National Cancer Institute (NCI) to study possible links between liver cancer and HIV.
Vincent Lo Re, MD, MSCE
Lo Re will serve as a co-principal investigator alongside Amy Justice, MD, PhD, a professor of General Medicine and Public Health at Yale School of Public Health through 2021.
The project will investigate liver cancer among HIV-infected and uninfected veterans. People infected with HIV are about five times more likely to be diagnosed with liver cancer than uninfected people (and significantly more likely to be diagnosed with other types of cancer as well). As HIV-infected patients age, liver cancer-related deaths are expected to increase over time.
“Infection with HIV in general weakens the immune system and reduces the body's ability to fight cancer and other diseases,” said Lo Re, who is also serves as senior scholar in the Center for Clinical Epidemiology and Biostatistics. “Our aim is to provide information on how the biology of aging and HIV interact to promote liver cancer. These results could inform future interventions to decrease the incidence of liver cancer.”
Lo Re and Justice, and their research team, will use stored clinical biopsies from HIV-infected and uninfected veterans to determine if liver cancer operates differently in HIV-infected individuals because of their diminished immune function and higher levels of inflammation.
Despite the five-fold greater prevalence of liver cancer in HIV-infected patients, factors associated with its development in these patients remain largely unknown. Previous studies of liver cancer in HIV-infected patients have been limited by small numbers of liver cancer cases, short follow-up, inclusion of demographically different uninfected comparison groups, lack of inclusion of established risk factors for liver cancer, and concerns about generalizability to HIV-infected patients.
The project (grant number R01-CA206465) will address these knowledge gaps and limitations by merging over 15 years of electronic medical record data from HIV-infected and demographically similar uninfected patients in the Veterans Aging Cohort Study, the largest HIV cohort in North America, with liver cancer tissue specimens from these individuals.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.